Lessons from Real Life Experience: Importance of In-House Sequencing and Smart Ratio-Based Real-Time PCR Outperform Multiplex Ligation-Dependent Probe Amplification in Prenatal Diagnosis for Spinal Muscular Atrophy: Bench to Bedside Diagnosis

Abstract

Spinal muscular atrophy (SMA) is a rare, recessively inherited neurodegenerative disorder caused by the presence of pathogenic variants in the SMN gene. As it is the leading inherited cause of infant mortality, identification of SMN gene pathogenic variant carriers is important for diagnostic purposes with effective genetic counseling. Multiple ligation probe analysis (MLPA), a probe-based method, is considered as the gold standard for SMA carrier analysis. However, MLPA might give false-negative results in cases with variations in the probe-binding regions. Here, we present a case born to consanguineous SMA carrier parents. Prenatal diagnosis with MLPA failed to detect the compound heterozygous mutant state of the proband and she was born unfortunately with SMA phenotype. Further analysis with a real-time polymerase chain reaction kit was able to detect the compound heterozygous state of the patient and was confirmed with targeted next-generation sequencing technology.

Keywords

SMA - SMN1 - MLPA - sequencing - in-house testing

Publication History

Article published online:
31 August 2023

• References

• 1 Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Arch Neurol 2011; 68 (08) 979-984
• 2 Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr Neurol 1999; 3 (02) 49-51
• 3 Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015; 33 (04) 831-846
• 4 Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015; 51 (02) 157-167
• 5 Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci 1997; 146 (01) 67-72
• 6 Piepers S, van den Berg LH, Brugman F. et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol 2008; 255 (09) 1400-1404
• 7 Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. J Child Neurol 2007; 22 (08) 990-994
• 8 Pellizzoni L. Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep 2007; 8 (04) 340-345
• 9 Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat Rev Neurosci 2009; 10 (08) 597-609
• 10 Mailman MD, Heinz JW, Papp AC. et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4 (01) 20-26
• 11 Han JJ, McDonald CM. Diagnosis and clinical management of spinal muscular atrophy. Phys Med Rehabil Clin N Am 2008; 19 (03) 661-680 , xii
• 12 Oskoui M, Levy G, Garland CJ. et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007; 69 (20) 1931-1936
• 13 Foust KD, Wang X, McGovern VL. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28 (03) 271-274
• 14 Passini MA, Bu J, Roskelley EM. et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010; 120 (04) 1253-1264
• 15 Dominguez E, Marais T, Chatauret N. et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011; 20 (04) 681-693
• 16 Jiang L, Lin R, Gallagher S, Zayac A, Butchbach MER, Hung P. Development and validation of a 4-color multiplexing spinal muscular atrophy (SMA) genotyping assay on a novel integrated digital PCR instrument. Sci Rep 2020; 10 (01) 19892
• 17 Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet 2021; 14: 11-25
• 18 Prior TW, Nagan N. Spinal muscular atrophy: overview of molecular diagnostic approaches. Curr Protoc Hum Genet 2016; 88: 9.27.1-9.27.13
• 19 Stuppia L, Antonucci I, Palka G, Gatta V. Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci 2012; 13 (03) 3245-3276
• 20 Arkblad EL, Darin N, Berg K. et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord 2006; 16 (12) 830-838
• 21 Sharifi Z, Forouzesh F, Taheri M, Zeinali S. Constraints of carrier screening in spinal muscular atrophy: Co-existence of deletion and duplication in SMN1 gene and false negative MLPA result. Gene Rep 2019; 16: 100440
• 22 Wu S, Li YL, Cheng NY. et al. c.835-5T>G variant in SMN1 gene causes transcript exclusion of exon 7 and spinal muscular atrophy. J Mol Neurosci 2018; 65 (02) 196-202
• 23 Lefebvre S, Bürglen L, Reboullet S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80 (01) 155-165
• 24 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424